Cardiovascular mortality · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of sleep · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
AHI · adults with central sleep apnoea associated with heart failure
1 finding from 1 review
All‐cause mortality · adults with central sleep apnoea associated with heart failure
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response at 8 weeks · Patients with active or quiescent lymphocytic colitis
Beclometasone dipropionate showed no clear difference in clinical response at 8 weeks compared with mesalazine (low certainty).
1 finding from 1 review
Maintenance of clinical response · Patients with active or quiescent lymphocytic colitis
It is very uncertain whether beclometasone dipropionate changes maintenance of clinical response at 12 weeks compared with mesalazine (very low certainty).
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Goel 2015 (3-arm: intralesional betamethasone vs lycopene vs placebo, 90 per arm): appeared to show increased interincisal distance in both intervention groups vs placebo, but only between-group differences with no…
1 study · 180 participants
GRADE not reported
Duration of treatment (days) · Adults (>18 years) with established dry socket following permanent tooth extraction
Metronidazole (intrasocket) led to lower duration of treatment (days) compared with placebo; GRADE not reported.
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the short terma · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in laxation response: risk of spontaneous rescue‐free bowel… compared with higher dose (low certainty).
1 finding from 1 review
Laxation response: risk of spontaneous rescue‐free bowel movements in the medium termb · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
It is very uncertain whether methylnaltrexone lower dose changes laxation response: risk of spontaneous rescue‐free bowel… compared with higher dose (very low certainty).
1 finding from 1 review
Laxation response: patient assessment of change in bowel status at the end of trial · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in laxation response: patient assessment of change in bowel statusgat… compared with higher dose (low certainty).
1 finding from 1 review
Symptoms of opioid withdrawal in the medium term · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in symptoms of opioid withdrawal in the medium term compared with higher dose (low certainty).
1 finding from 1 review
Serious adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people receiving palliative care irrespective of whether they had cancer with opioid‐induced bowel dysfunction
Methylnaltrexone lower dose showed no clear difference in adverse events compared with higher dose (low certainty).
1 finding from 1 review
Clinical resolution · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Intralesional betamethasone may leads to higher clinical resolution compared with intralesional triamcinolone acetonide (low certainty).
1 finding from 1 review
Clinical score (14 days) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
It is very uncertain whether intralesional betamethasone changes clinical score (14 days) compared with intralesional triamcinolone acetonide (very low certainty).
1 finding from 1 review
Health‐related quality of life · adults (>= 18 years) with an irreversible visual impairment
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Vision‐related quality of life · adults (>= 18 years) with an irreversible visual impairment
1 finding from 1 review